Gordon Carl L: insider trades.
Gordon Carl L reported 22 non-derivative transactions on 10 SEC ownership filings in Q3 2026: 7 open-market purchases ($61.1M) and 0 sales, across 4 companies.
- Transactions
- 22
- Purchases (P)
- 7
- Sales (S)
- 0
- Companies
- 4
- Name as filed
- GORDON CARL L
Companies
| Company | Relationship | Transactions |
|---|---|---|
| ADARx Pharmaceuticals, Inc. (ADRX) | Director, TenPercentOwner | 11 |
| Electra Therapeutics, Inc. (ETRA) | Director, TenPercentOwner | 6 |
| BlossomHill Therapeutics, Inc. (BLSM) | Director | 3 |
| Scribe Therapeutics, Inc. (SCTX) | Director | 2 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 10,690,530 | — | 10,690,530 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 2,000,962 | — | 12,691,492 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 769,601 | — | 13,461,093 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 564,187 | — | 14,025,280 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | P | 300,249 | $17 | 14,325,529 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | P | 588,235 | $17 | 588,235 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 1,333,975 | — | 8,460,994 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 513,067 | — | 8,974,061 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 256,448 | — | 9,230,509 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | P | 61,516 | $17 | 9,292,025 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 7,127,019 | — | 7,127,019 | Form 4 |
| 2026-09-21 | Electra Therapeutics, Inc. | P | 333,333 | $15 | 5,126,891 | Form 4 |
| 2026-09-21 | Electra Therapeutics, Inc. | C | 1,703,314 | — | 4,793,558 | Form 4 |
| 2026-09-21 | Electra Therapeutics, Inc. | P | 1,000,000 | $15 | 1,758,279 | Form 4 |
| 2026-09-21 | Electra Therapeutics, Inc. | C | 1,087,934 | — | 3,090,244 | Form 4 |
| 2026-09-21 | Electra Therapeutics, Inc. | C | 2,002,310 | — | 2,002,310 | Form 4 |
| 2026-09-21 | Electra Therapeutics, Inc. | C | 758,279 | — | 758,279 | Form 4 |
| 2026-08-10 | BlossomHill Therapeutics, Inc. | C | 1,049,283 | — | 2,089,279 | Form 4 |
| 2026-08-10 | BlossomHill Therapeutics, Inc. | C | 1,039,996 | — | 1,039,996 | Form 4 |
| 2026-08-10 | BlossomHill Therapeutics, Inc. | P | 625,000 | $16 | 2,714,279 | Form 4 |
| 2026-07-27 | Scribe Therapeutics, Inc. | P | 1,000,000 | $15 | 1,348,825 | Form 4 |
| 2026-07-27 | Scribe Therapeutics, Inc. | C | 348,825 | — | 348,825 | Form 4 |
Questions
What stock did Gordon Carl L buy or sell?
Gordon Carl L reported 22 non-derivative transactions on 10 SEC ownership filings in Q3 2026: 7 open-market purchases ($61.1M) and 0 sales, across 4 companies.
Is Gordon Carl L the same person as other filers with this name?
This page covers SEC CIK 1282930 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/gordon-carl-l-1282930.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.